KRTL International Corp and KRTL Biotech Inc., a wholly owned subsidiary of KRTL Holding Group, Inc. KRTL have occurred Memorandum of Understanding for the development of industry-differentiated commercial CBD and other cannabinoid based products with Yuhan Carea subsidiary of Yuhan Corporation.

“We are honored that Yuhan Care is collaborating with us at KRTL, they are natural health care professionals who have inherited innovative research expertise from Yuhan Corporation, a 100-year-old company with an unblemished reputation in Korea and around the world. Their commitment to quality and transparency is something we strive for at KRTL and a standard that everyone in the pharmaceutical industry should aspire to. This agreement allows KRTL to take an incredible strategic step towards our commercial efforts in Korea as the country progresses towards legalization based on the Hemp Free Zone work, and enables a trusted and meaningful bridge for CBD products, coming to the US from Korea – something that’s never been done before,” said Kai KimCEO of KRTL International Corporation.

Under the MOU, KRTL will partner with Yuhan to develop cannabinoid-based products targeting the commercial markets in the U.S. and Korea, develop distribution channels and partners, and collaborate on various R&D projects within the Korea Hemp Free Zone and across the U.S. This agreement details the exclusive use of KRTL’s CBD manufacturing partners, who are cGMP compliant, FDA accredited, and certified ISO/IEC 17025 facilities located in the United States, for the sole sourcing of cannabinoid-based products derived from emerge from this agreement.

Get your daily dose of Cannabis News on Benzinga cannabis. Don’t miss any important developments in the industry.

Photo: Benzinga; Sources: courtesy of Jarmoluk and Lindsayfox via Pixabay

Similar news

Launch of the CBD training academy in South Korea